Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis-->Fischer 344 model of chronic allograft rejection.
暂无分享,去创建一个
B Murphy | M. Sayegh | W. Hancock | B. Murphy | R. Buelow | K S Kim | R Buelow | M H Sayegh | W W Hancock | K. S. Kim
[1] D. Candinas,et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment , 1997, Nature Medicine.
[2] J. Fechner,et al. Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. , 1996, Transplantation.
[3] M. Sayegh,et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. , 1996, The Journal of clinical investigation.
[4] J. Drazen,et al. Sorting out the cytokines of asthma , 1996, The Journal of experimental medicine.
[5] L. Gao,et al. A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. , 1995, Transplantation.
[6] L. Paul. Chronic renal transplant loss. , 1995, Kidney international.
[7] S. Ménoret,et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the alpha 1 helix of the first domain of HLA-B7 01. , 1995, Transplantation.
[8] C. Clayberger,et al. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. , 1995, Transplantation.
[9] S. Tullius,et al. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. , 1995, Transplantation.
[10] D. Adams,et al. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. , 1994, The American journal of pathology.
[11] L. Tian,et al. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. , 1994, Journal of immunology.
[12] T. Hostetter. Chronic transplant rejection. , 1994, Kidney international.
[13] R. Guttmann,et al. Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model. , 1994, Transplantation.
[14] A. Krensky,et al. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. , 1994, Journal of immunology.
[15] W. Baldwin,et al. CYTOKINES, ADHESION MOLECULES, AND THE PATHOGENESIS OF CHRONIC REJECTION OF RAT RENAL ALLOGRAFTS , 1993, Transplantation.
[16] B. Fellström,et al. Chronic vascular rejection of the heart and the kidney--have rational treatment options emerged? , 1992, Transplantation.
[17] P. Parham,et al. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2 domain of HLA–A2 , 1987, Nature.
[18] A. Krensky,et al. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. , 1993, Transplantation proceedings.
[19] P. Parham,et al. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes , 1987, Nature.